

Dupuytren's Contracture

BEFORE providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate **EXPLICIT CONSENT** for sensitive and personal information on this form to be passed to the Funding Team/CCG/CSU for processing.

Consent given: Yes

Please ensure a secure NHSmail email account (nhs.net) is used to submit this form.

Patient First name		Patient Surname		Hospital	
NHS No.		Date of Birth		Consultant	
GP F-code		CCG		UBRN	
Hospital No.		Referrer			

Additional information

Please submit completed form to the following email address:

bbccg.mseccg-funding@nhs.net

A decision will be made and the form returned within **3 working days** where all relevant information is provided.

N.B: Please ensure forms are clear and legible. Illegible forms will be returned to sender.

Patients can only be referred for funding if they meet ONE of the sets of criteria below (A OR B).		Please Tick ✓
Please indicate <input type="checkbox"/> which of the criteria <input type="checkbox"/> patient meets:		
A	<ul style="list-style-type: none"> Metacarpophalangeal joint (MCPJ) joint contracture of 30° or more and/or proximal IP joint contracture of 20° or more (inability to place hand flat on table) 	
OR	<ul style="list-style-type: none"> Severe thumb contractors 	
AND	<ul style="list-style-type: none"> Where such condition (either MCPJ or PIPJ) is severely impacting on activity of daily living 	
OR B	<ul style="list-style-type: none"> Young patients with early onset disease (25-40) +/- family history, who may benefit from early assessment. 	

Please provide detail loss of extension and function impairment here:

The Prior Approval form and Referral Letter should detail the degree of contracture/loss of extension and functional impairment in line with criteria above

The use of Collagenase clostridium histolyticum (Xiapex®) is only supported in line with NICE TA459

- People who meet the inclusion criteria for the ongoing clinical trial (HTA-15/102/04), comparing collagenase clostridium histolyticum (CCH) with limited fasciectomy, are encouraged to participate in the study.
- For people not taking part in the ongoing clinical trial, CCH is recommended as an option for treating Dupuytren's contracture with a palpable cord in adults only if all of the following apply:
 - There is evidence of moderate disease (functional problems and metacarpophalangeal joint contracture of 30° to 60° and proximal interphalangeal joint contracture of less than 30° or first web contracture) plus up to 2 affected joints.
 - Limited fasciectomy is considered appropriate by the treating hand surgeon.
 - The choice of treatment (CCH or limited fasciectomy) is made on an individual basis after discussion between the responsible hand surgeon and the patient about the risks and benefits of the treatments available.
 - One injection is given per treatment session by a hand surgeon in an outpatient setting. ME&SCCGs will not fund any activity/treatments costs associated with administration of CCH in any other circumstances. **Individual funding approval is required for each injection (High Cost Drug proforma).**

The following surgery/treatments are considered to be a low clinical priority and are not routinely funded.

- Needle aponeurotomy (also known as percutaneous needle fasciotomy)
- Radiation therapy for early Dupuytren's contracture
- Simple nodules in the palm

CCG USE:	Invoice ref:	Prior Authorisation requested by:	
Is the procedure approved or declined?		Name of Clinician	
<small>Please indicate:</small>			
Name		Contact number	
Signature		Date	
Date			